source
- ‘We’re getting back to stability’: CBER Director Karim Mikhail shares his strategy with FierceThe FDA's Center for Biologics Evaluation and Research (CBER) is recovering from the most turbulent period in its recent history. The captain tasked with steadying the ship is Karim Mikhail, who wa…Fierce Biotech · 11d ago↗ source
- Endeavor BioMedicines reports positive phase 2b results for Hedgehog inhibitor taladegib in IPFEndeavor BioMedicines announced that its Hedgehog pathway inhibitor, taladegib, produced encouraging results in a phase 2b study of patients with idiopathic pulmonary fibrosis (IPF). The trial, nam…